Oppenheimer analyst Christopher Marai reiterated an Outperform rating and $28 price target on Xencor, Inc. (NASDAQ: XNCR) saying they would ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View FDA

Xencor, Inc. (XNCR) Misses Q3 EPS by 7cNovember 3, 2015 4:41 PM Xencor Reports Third Quarter 2015 Financial Results and Pipeline UpdateNovember 3, 2015 4:01 PM